Altered vitamin K biodistribution and metabolism in experimental and human chronic kidney disease.


Journal

Kidney international
ISSN: 1523-1755
Titre abrégé: Kidney Int
Pays: United States
ID NLM: 0323470

Informations de publication

Date de publication:
02 2022
Historique:
received: 28 05 2021
revised: 07 10 2021
accepted: 18 10 2021
pubmed: 15 11 2021
medline: 12 3 2022
entrez: 14 11 2021
Statut: ppublish

Résumé

Chronic kidney disease (CKD) is accompanied with extensive cardiovascular calcification, in part correlating with functional vitamin K deficiency. Here, we sought to determine causes for vitamin K deficiency beyond reduced dietary intake. Initially, vitamin K uptake and distribution into circulating lipoproteins after a single administration of vitamin K1 plus K2 (menaquinone 4 and menaquinone 7, respectively) was determined in patients on dialysis therapy and healthy individuals. The patients incorporated very little menaquinone 7 but more menaquinone 4 into high density lipoprotein (HDL) and low-density lipoprotein particles than did healthy individuals. In contrast to healthy persons, HDL particles from the patients could not be spiked with menaquinone 7 in vitro and HDL uptake was diminished in osteoblasts. A reduced carboxylation activity (low vitamin K activity) of uremic HDL particles spiked with menaquinone 7 vs. that of controls was confirmed in a bioassay using human primary vascular smooth muscle cells. Kidney menaquinone 4 tissue levels were reduced in 5/6-nephrectomized versus sham-operated C57BL/6 mice after four weeks of a vitamin K rich diet. From the analyzed enzymes involved in vitamin K metabolism, kidney HMG-CoA reductase protein was reduced in both rats and patients with CKD. In a trial on the efficacy and safety of atorvastatin in 1051 patients with type 2 diabetes receiving dialysis therapy, no pronounced vitamin K deficiency was noted. However, the highest levels of PIVKA-II (biomarker of subclinical vitamin K deficiency) were noted when a statin was combined with a proton pump inhibitor. Thus, profound disturbances in lipoprotein mediated vitamin K transport and metabolism in uremia suggest that menaquinone 7 supplementation to patients on dialysis therapy has reduced efficacy.

Identifiants

pubmed: 34774554
pii: S0085-2538(21)01056-5
doi: 10.1016/j.kint.2021.10.029
pii:
doi:

Substances chimiques

Vitamin K 2 11032-49-8
Vitamin K 12001-79-5
Vitamin K 1 84-80-0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

338-348

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Auteurs

Nadine Kaesler (N)

Department of Nephrology and Clinical Immunology, Rheinisch-Westfälische Technische Hochschule Aachen University Hospital, Aachen, Germany; Institute of Experimental Medicine and Systems Biology, Rheinisch-Westfälische Technische Hochschule Aachen University Hospital, Aachen, Germany. Electronic address: nkaesler@ukaachen.de.

Felix Schreibing (F)

Department of Nephrology and Clinical Immunology, Rheinisch-Westfälische Technische Hochschule Aachen University Hospital, Aachen, Germany; Institute of Experimental Medicine and Systems Biology, Rheinisch-Westfälische Technische Hochschule Aachen University Hospital, Aachen, Germany.

Thimoteus Speer (T)

Department of Internal Medicine, Nephrology and Hypertension and Cardio-Renal Medicine, Saarland University Medical Centre, Homburg, Saar, Germany; Translational Cardio-Renal Medicine, Saarland University, Homburg/Saar, Germany.

Sofia de la Puente-Secades (S)

Institute of Molecular and Cardiovascular Research, Rheinisch-Westfälische Technische Hochschule Aachen University Hospital, Aachen, Germany.

Nikolas Rapp (N)

Department of Biochemistry, Cardiovascular Research School Maastricht, Maastricht University, Maastricht, the Netherlands.

Christiane Drechsler (C)

Division of Nephrology, University Hospital Würzburg, Würzburg, Germany.

Nazanin Kabgani (N)

Institute of Experimental Medicine and Systems Biology, Rheinisch-Westfälische Technische Hochschule Aachen University Hospital, Aachen, Germany.

Christoph Kuppe (C)

Department of Nephrology and Clinical Immunology, Rheinisch-Westfälische Technische Hochschule Aachen University Hospital, Aachen, Germany; Institute of Experimental Medicine and Systems Biology, Rheinisch-Westfälische Technische Hochschule Aachen University Hospital, Aachen, Germany.

Peter Boor (P)

Department of Nephrology and Clinical Immunology, Rheinisch-Westfälische Technische Hochschule Aachen University Hospital, Aachen, Germany; Institute of Pathology, Rheinisch-Westfälische Technische Hochschule Aachen University Hospital, Aachen, Germany.

Vera Jankowski (V)

Institute of Molecular and Cardiovascular Research, Rheinisch-Westfälische Technische Hochschule Aachen University Hospital, Aachen, Germany.

Leon Schurgers (L)

Department of Nephrology and Clinical Immunology, Rheinisch-Westfälische Technische Hochschule Aachen University Hospital, Aachen, Germany; Institute of Experimental Medicine and Systems Biology, Rheinisch-Westfälische Technische Hochschule Aachen University Hospital, Aachen, Germany; Department of Biochemistry, Cardiovascular Research School Maastricht, Maastricht University, Maastricht, the Netherlands.

Rafael Kramann (R)

Department of Nephrology and Clinical Immunology, Rheinisch-Westfälische Technische Hochschule Aachen University Hospital, Aachen, Germany; Institute of Experimental Medicine and Systems Biology, Rheinisch-Westfälische Technische Hochschule Aachen University Hospital, Aachen, Germany; Department of Internal Medicine, Nephrology and Transplantation, Erasmus Medical Center, Rotterdam, the Netherlands.

Jürgen Floege (J)

Department of Nephrology and Clinical Immunology, Rheinisch-Westfälische Technische Hochschule Aachen University Hospital, Aachen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH